Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (142)	11/9/1998 10:25:00 AM
From: Omer Shvili	Read Replies (1) \| Respond to of 1386

Tom, Dr. Tracy is the editor of Neuroinvestor, a very informative (and I believe, the only newsletter devoted to biotechs who are active in different neurological research) newsletter. Dr. Tracy has a background in the field of neurology, so unlike most of us, he understand everything PARS says. I try to do my homework and learn as much as I can, but I'll never reach the level of understanding like Dr. Tracy. PARS' management also respects him greatly, and admit that he's one of very few investors who really understand what PARS is doing, as his background is in this field. Dr. Tracy posts on SI under the name Neuroinvestor, but you can read his insights on his web-site neuroinv.com His newsletter is a must for people who invest in biotechs in this field. Omer

To: tom pope who wrote (142)	11/9/1998 11:56:00 AM
From: Merav	Read Replies (2) \| Respond to of 1386

Front page BioWorld Int'l article describes dexanabinol as the most promising neuroprotective agent seen to date according to a world authority on head trauma. If you're wondering why an astute pharma company like Agis wants to own shares in Pharmos, suggest getting ahold of Nov. 4 edition vol 3, no. 44: "Dexanabinol is the most promising neuroprotective agent seen to date," said Lawrence Marshall, a world authority on outcome after head trauma. Marshall is chief of neurological surgery at the University of California at San Diego. The article is quite lengthy and goes on to quote Dr. Marshall as saying: "Phase II clinical trial results present outstanding and objective evidence via a pattern of intracranial pressure reduction with significantly improved outcome in severe head injury," said Marshall.